Exclusive Generic Launches at Teva - Analyst Blog - NASDAQ

30-09-2013 NASDAQComments (0)


Teva Pharmaceutical Industries Ltd.'s ( TEVA ) generics business has been performing below expectations over the past few quarters. Second quarter 2013 generics business sales in the U.S. were soft with revenues declining 8% to $970 million. Lower ...

Read more on NASDAQ

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top